Everest Medicines Limited

1952

KYG3224E1061

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 16:08:30 12/01/2026 HKT			5-day change	1st Jan Change
39.28 ^HKD	+0.31%		-1.06%	+6.22%

12-31	Everest Medicines says chairman purchases 30,000 shares for HK$1.139 million	RE
12-30	Everest Medicines aware that generic drug to Nefecon approved by NMPA in China	RE

Everest Medicines Says Exec Director & CEO Not Disposed Of Any Shares

Published on 06/13/2025 at 09:36 am HKT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Everest Medicines Limited

12-31	Everest Medicines says chairman purchases 30,000 shares for HK$1.139 million	RE
12-30	Everest Medicines aware that generic drug to Nefecon approved by NMPA in China	RE
12-30	Everest Medicines Limited Announces Approval of Generic Drug to NEFECON®?	CI
12-15	Everest Medicines Executives Buy Shares	MT
12-15	Everest Medicines says chairman, others purchased shares of co on Dec 12	RE
12-11	Everest Medicines Limited Appoints Xin Sun as Non-Executive Director with Effect from 11 December 2025	CI
31/10/25	Certain Ordinary Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending on 31-OCT-2025.	CI
30/10/25	Everest Medicines Acquires License to Eye Drug for $7 Million Upfront	MT
30/10/25	Everest Medicines announces agreement with Visara	RE
30/10/25	Everest Medicines Limited Enters into an Agreement with Visara, Inc	CI
10/10/25	Everest Medicines Chairman Steps Down; Successor Named	MT
10/10/25	Everest Medicines's Wei Fu ceases to be chairman	RE
10/10/25	Everest Medicines Limited Announces Board and Committee Changes, Effective 10 October 2025	CI
29/08/25	Everest Medicines Limited, H1 2025 Earnings Call, Aug 29, 2025
29/08/25	Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise	MT
29/08/25	Everest Medicines Limited Provides Earning Guidance for the Full Year 2025	CI
29/08/25	Everest Medicines Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/08/25	I-Mab announced that it expects to receive $30.9 million in funding from Everest Medicines Limited, Janus Henderson Investors, Adage Capital Management, L.P., Woodline Partners LP, Exome Asset Management LLC	CI
04/08/25	Everest Medicines Subscribes for 15.8 Million ADSs in Global Biotech Firm; Shares Jump 8%	MT
01/08/25	Everest Medicines subscribes for 15.8 million ADSs of I-Mab for $30.9 million	RE
01/08/25	Everest Medicines expands strategic investment in I-Mab	RE
25/07/25	Everest Medicines to Raise HK$1.6 Billion via Top-Up Placement	MT
25/07/25	Everest Medicines to place 22.6 million new shares at HK$69.70 per share	RE
04/07/25	Everest Medicines Limited - Special Call
13/06/25	Everest Medicines' Controlling Shareholder to Offload 25 Million Shares	MT

Chart Everest Medicines Limited

Duration

Period

1952: Dynamic Chart

Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Companyâs products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.

Employees

722

Sector

Pharmaceuticals

Calendar

01-15 - J.P. Morgan Healthcare Conference

More about the company